The Library
Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults
Tools
Tools
Tools
Murray, Robert D., Randeva, Harpal S., Lewandowski, Krzysztof C., Komorowski, J., Lawrance, Jeremy A., Adams, Judith E. and Shalet, Stephen M. (2011) Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults. Growth Hormone & IGF Research, Vol.21 (No.2). pp. 96-101. doi:10.1016/j.ghir.2011.02.002
Full text not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1016/j.ghir.2011.02.002
Abstract
Objective: GHD adults exhibit a number of adverse surrogate markers of vascular risk culminating in excess vascular morbidity and mortality. Vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of a number of vascular morbidities. Furthermore, serum levels decrease following GH replacement in GHD adults, though it remains unclear if levels are significantly elevated in untreated individuals.
Design: A cross-sectional case-control study.
Methods: We measured fasting serum VEGF. MMP2, and MMP9 in 27 patients with GHD, 24 with partial GHD (CHI), and 25 sex- and age-matched controls.
Results: GHD (483 +/- 334 vs 326 +/- 180 ng/l, P = 0.04), but not all (354 +/- 192 vs 326 +/- 180 ng/l, P = n/s) adults had significantly elevated VEGF levels compared with controls. Neither MMP2, nor MMP9 levels were elevated in the patient groups. Serum VEGF levels correlated positively with LDL-cholesterol (R = 0.34, P = 0.004) and serum MMP9 values (R = 0.36, P = 0.002), and negatively with IGF-I values, however, no correlation was observed with MMP2. Multiple regression analysis with VEGF levels as the dependent variable, and age, gender, % fat mass, LDL-C, insulin and IGF-I as independent variables revealed VEGF levels to be dependent on LDL-C alone (P = 0.003, R = 0.36).
Conclusion: GHD adults have elevated VEGF levels, which correlate with MMP9 levels. Both VEGF and MMP9 are associated with vascular pathologies and may provide insight in to the pathophysiological mechanisms underlying the increased vascular morbidity and mortality observed in GHD adults. (C) 2011 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | Q Science > QP Physiology R Medicine > RC Internal medicine |
||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Medicine > Warwick Medical School |
||||
| Library of Congress Subject Headings (LCSH): | Vascular endothelial growth factors, Metalloproteinases, Dwarfism, Pituitary, Somatotropin | ||||
| Journal or Publication Title: | Growth Hormone & IGF Research | ||||
| Publisher: | Churchill Livingstone | ||||
| ISSN: | 1096-6374 | ||||
| Official Date: | April 2011 | ||||
| Dates: |
|
||||
| Volume: | Vol.21 | ||||
| Number: | No.2 | ||||
| Page Range: | pp. 96-101 | ||||
| DOI: | 10.1016/j.ghir.2011.02.002 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Funder: | Ipsen Ltd., Novo Nordisk, Pfizer Ltd., Eli Lilly and Company, Pharmacia ENI Diagnostics Inc. |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
